deltatrials
Unknown PHASE2 INTERVENTIONAL NCT00043433

Study of T900607-Sodium in Chemotherapy Naive Patients With Hepatocellular Carcinoma.

Sponsor: Tularik

Conditions Hepatocellular Carcinoma
Interventions intravenous T900607-sodium
Updated 6 times since 2017 Last updated: Jun 23, 2005 Started: Jul 31, 2002
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00043433, this PHASE2 trial focuses on Hepatocellular Carcinoma and remains ongoing. Sponsored by Tularik, it has been updated 6 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 9 months · monthly snapshotUnknown

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

Jul 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Tularik
Data source: Tularik

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations